ReviewImmunity2022
What SARS-CoV-2 does to our brains.
Review in Immunity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 44 citations in OpenAlex.
- Human brain matters: Navigating the neuropathology of COVID-19.Brain pathology (Zurich, Switzerland) · 2026Review
- New-Onset Myasthenia Gravis Associated with SARS-CoV-2 Infection: A Systematic Review.Life (Basel, Switzerland) · 2026Review
- Article
- Coronavirus disease 2019-related risk factors for postoperative delirium: a secondary analysis of an observational cohort study.International journal of surgery (London, England) · 2025Article
- Chronic Neuroplasticity Changes Following Neurotropic Viral Infection: Mechanisms and Implications.Cellular and molecular neurobiology · 2025Review
- A survey of SARS-CoV-2 tropism.Infectious diseases & immunity · 2025Review
- Modelling human brain development and disease with organoids.Nature reviews. Molecular cell biology · 2025Review
- Antibodies against SARS-CoV-2 spike protein in the cerebrospinal fluid of COVID-19 patients and vaccinated controls: a multicentre study.Journal of neurology · 2024Article
- Hospitalization for SARS-CoV-2 and the risk of self-harm readmission: a French nationwide retrospective cohort study.Epidemiology and psychiatric sciences · 2024Article
- Proteomic and transcriptomic profiling of brainstem, cerebellum and olfactory tissues in early- and late-phase COVID-19.Nature neuroscience · 2024Article
- HIV and COVID-19: two pandemics with significant (but different) central nervous system complications.Free neuropathology · 2024Article
- Exploring the role of galectin-9 and artemin as biomarkers in long COVID with chronic fatigue syndrome: links to inflammation and cognitive function.Frontiers in immunology · 2024Article
- Role of microglia in brain development after viral infection.Frontiers in cell and developmental biology · 2024Review
- SARS-CoV-2-associated T-cell infiltration in the central nervous system.Clinical & translational immunology · 2024Article
- Mendelian randomization reveals no causal relationship between COVID-19 susceptibility, hospitalization, or severity and epilepsy.Epilepsia open · 2023Article
- Article
- Article
- Are the Post-COVID-19 Posttraumatic Stress Disorder (PTSD) Symptoms Justified by the Effects of COVID-19 on Brain Structure? A Systematic Review.Journal of personalized medicine · 2023Review
- [COVID-19: Neurological manifestations and complications during the acute phase of the disease].Bulletin de l'Academie nationale de medecine · 2023Review
- SARS-CoV-2 and the nervous system: current perspectives.Archives of virology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurological symptoms in SARS-CoV-2-infected patients have been reported, but their cause remains unclear. In theory, the neurological symptoms observed after SARS-CoV-2 infection could be (1) directly caused by the virus infecting brain cells, (2) indirectly by our body's local or systemic immune response toward the virus, (3) by coincidental phenomena, or (4) a combination of these factors. As indisputable evidence of intact and replicating SARS-CoV-2 particles in the central nervous system (CNS) is currently lacking, we suggest focusing on the host's immune reaction when trying to understand the neurocognitive symptoms associated with SARS-CoV-2 infection. In this perspective, we discuss the possible immune-mediated mechanisms causing functional or structural CNS alterations during acute infection as well as in the post-infectious context. We also review the available literature on CNS affection in the context of COVID-19 infection, as well as observations from animal studies on the molecular pathways involved in sickness behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.